| Patent
application NEWS re: AVR118/Product R & leukemia: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=hirschman&OS=hirschman&RS=hirschman - - - - - View Replies » |
| 4titudinous:
Incredible: [0016] Product R has been found to be effective in the treatment of cancers emanating from lymphocytic cells including patients with acute lymphocytic leukemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma. [0017] According to the present invention, Product R is preferably administered to the patient parenterally, while other administration routes such as nasal spray or ingestion may also be employed. A suitable effective dose of Product R will be in the range of from about 5 microliters to about 40 microliters per kilogram of body weight per day, preferably in the range of about 10 microliters to about 25 microliters per kilogram of body weight per day. Most preferably Product R is administered in an amount of about 30 microliters per kilogram of body weight per day for about one week, followed by about 15 microliters per kilogram of body weight per day in a sterile injectable formulation. The desired dose may be administered as two, three or more sub-doses at appropriate intervals, generally equally spread in time, throughout the day. Preferably, the full daily dose is administered in one administration. [0018] Alternatively, Product R may be administered to the patients according to the conventional dosages or any dosages that are apparent to a person of ordinary skill in the art. [0019] Product R may be administered by any suitable injection route including, but not limited to intravenously, intraperitoneally, subcutaneously, intramuscularly, and intradermally, etc. The presently preferred route of administration is intramuscularly. It will be appreciated that the preferred route may vary with, for example, the condition and age of the recipient. [0020] Product R may be used in therapy in conjunction with other medicaments including corticosteroid, gamma globulin, glucose, or vitamins, antiviral agents such as interferon or interleukin, etc. [0021] The present invention is further provide a method for treating patients suffering from non-solid tumors such as Lymphocytic Leukemias, Hodgkin's Disease and Non/Hodgkin's Lymphoma by administering the active components or active portion(s) of Product R to such patients. The active components or portions of Product R are described in the above mentioned U.S. Pat. Nos. 6,303,153 and 6,528,098. [0022] While it is possible for Product R to be administered as part of a pharmaceutical formulation, it is preferable to present it alone, although it may be administered at about the same time as one or more other pharmaceuticals are independently administered. If Product R is administered as part of a pharmaceutical formulation, the formulations of the present invention comprise at least one administered ingredient, i.e. Product R, as above defined, together with one or more acceptable carriers thereof and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. |
| Bummer!!!
Survives the disease but a fall kills him!! EXAMPLE 1 [0027] In a 71 year old white male with acute lymphocytic leukemia who failed intensive courses of conventional chemotherapy, Product R was effective in keeping this patient alive for 18 months. Chemotherapy was discontinued soon after commencing Product R therapy. Indeed, after commencing Product R therapy the patient's bone marrow which had contained 30% blast cells lost these blast cells. In addition, blast cells disappeared from the peripheral blood. During this two year period the patient put on weight, had a normal appetite, claimed that he felt well, and was able to live a normal quality of life. The patient died soon after a fall in his home. |
| 4titudinous:
All these patent applications are so very important. I have my eye on
this one also. I believe it's still in the application mode: United States Patent Application 20010006682 Kind Code A1 HIRSCHMAN, SHALOM Z. July 5, 2001 METHOD FOR TREATING PATIENTS WITH SUPPRESSED IMMUNE SYSTEMS "[0007] Cancer patients often exhibit a suppressed immune response. This immunosuppression is most likely caused by agents used to treat the cancer as well as by factors secreted by the cancer cells themselves. Most anti-cancer agents, such a radiation therapy and chemotherapy, inadvertently destroy lymphocytes and other cells important to the immune system. Some tumors, such as the tumors in Hodgkin's disease, release or induce the release of immunosuppressive factors. Hodgkin's disease patients exhibit an abnormally high sensitivity to intracellular parasitic infections such as tuberculosis and herpes virus infections. [0008] Viruses have developed several ways of suppressing the host immune response. Some viruses, such as HIV, target at the host immune system, resulting in a complete destruction of the system. In general, viruses can invade and suppress the host system by infecting T or B cells and abrogate their function, or infecting the thymus and inducing tolerance, or destroying speciallized antigen-presenting cells." http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220010006682%22.PGNR.&OS=DN/20010006682&RS=DN/20010006682 |
| Larry,
Patent Application: By: 4titudinous 19 Feb 2004, 08:46 AM EST Msg. 139221 of 139237 Patent application NEWS re: AVR118/Product R & leukemia: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=hirschman&OS=hirschman&RS=hirschman |
| 1st
ISC Conference: ADVR TO PRESENT SCIENTIFIC PAPER AT INTERNATIONAL CANCER
CONFERENCE Dr. James D'Olimpio, Spokesman-at-large for ADVR is to present a paper entitled «Use of a Peptide Nucleic Acid in Cancer Regulation and Metastasis: A Preliminary Report of Bimodal Effects in Vitro». The paper is to be presented at the 1st ISC Conference on Cancer Chemotherapeutics-Molecular Targets, Pharmacology and Clinical Applications, which will take place in Florence, Italy from February 19-21, 2004. The conference is meant to provide a forum for the dissemination of the latest knowledge in the field of anticancer drug research and development, and is jointly sponsored by the International Society of Chemotherapy and the Societ Italiana di Chemioterapia. Dr. DOlimpio will be presenting the results of scientific research spearheaded and conducted by the companys scientists, Dr. Maribel deDiego and Dr. Sharon Malia on the effects of AVR118 against tumor cell lines in vitro. http://www.adviral.com/ADVR/update/progress/progress.htm |
|
ISC International Society of Chemotherapy |
1st International Conference on Cancer Therapeutics |
SIC Societą Italiana di Chemioterapia |
|
|
Molecular Targets, Pharmacology and Clinical Applications |
|
|
|
|
|||
 |
|
||
| February 19-21, 2004 | |||
| Palazzo dei Congressi, Firenze, Italy | |||